

# PRODUCT INFORMATION



## GSK429286A

Item No. 15262

CAS Registry No.: 864082-47-3

Formal Name: N-(6-fluoro-1H-indazol-5-yl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-3-pyridinecarboxamide

MF:  $C_{21}H_{16}F_4N_4O_2$

FW: 432.4


Purity:  $\geq 98\%$

UV/Vis.:  $\lambda_{max}$ : 282, 362 nm

Supplied as: A crystalline solid

Storage:  $-20^{\circ}\text{C}$

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



### Laboratory Procedures

GSK429286A is supplied as a crystalline solid. A stock solution may be made by dissolving the GSK429286A in the solvent of choice. GSK429286A is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of GSK429286A in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF.

GSK429286A is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GSK429286A should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. GSK429286A has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

GSK429286A is a cell-permeable inhibitor of Rho-associated kinase ( $IC_{50} = 14 \text{ nM}$ ).<sup>1</sup> It less potently inhibits p90 and p70 ribosomal S6 kinases ( $IC_{50}$ s = 780 and 1,940 nM, respectively) and is ineffective against leucine-rich repeat protein kinase-2.<sup>1,2</sup> GSK429286A reverses adrenalin-induced contraction of rat aortic rings ( $IC_{50} = 190 \text{ nM}$ ) and produces a dose-dependent decrease in mean arterial pressure in spontaneously-hypertensive rats.<sup>1</sup>

### References

1. Goodman, K.B., Cui, H., Dowdell, S.E., *et al.* Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. *J. Med. Chem.* **50**(1), 6-9 (2007).
2. Nichols, R.J., Dzamko, N., Hutti, J.E., *et al.* Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. *Biochem. J.* **424**(1), 47-60 (2009).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/22/2016

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM